Medindia
Medindia LOGIN REGISTER
Advertisement

Paul Capital Healthcare Leads Panel on Strategic Financing

Monday, June 9, 2008 General News
Advertisement
NEW YORK and LONDON, June 9 Paul Capital Healthcare todayannounced that London-based partner Ken Macleod, Ph.D., will moderate a panelon strategic biotechnology financing at the BioFinance and BioInnovate Europe08 conference. Designed to familiarize participants with how to use revenuestreams as a strategic approach to financing, the panel, "Feeding the Beast:Structured Revenue Financing as a Strategy for Meeting Biotechnology's CapitalNeeds," is scheduled for 3:00 pm BST today. The conference, which is sponsoredby the Biotechnology Industry Association, will be held at the Royal Collegeof Physicians in London.
Advertisement

In addition to Dr. Macleod, the panel also will include Kristian Wiggert,Partner in the London office of Morrison & Foerster, and Steven Powell, Ph.D.,Chief Executive Officer of Plethora Solutions Holdings PLC. Dr. Macleod willprovide an overview and case studies of royalty and structured revenuefinancing transactions, Mr. Wiggert will discuss the legal considerations ofthese transactions and Dr. Powell will speak on the strategic rationale andmechanics of his company's recent revenue interest agreement with Paul CapitalHealthcare.
Advertisement

"Structured revenue financing and royalty monetization transactions arebecoming a standard financing strategy because they provide access to non-dilutive capital under flexible terms that can be structured to meet diverseobjectives," said Dr. Macleod. "Companies and institutions can structurethese transactions to provide capital for near-term initiatives whileretaining a substantial portion of the long-term value and upside potential oftheir royalty and revenue streams. This panel presentation is designed toprovide participants with real-life examples of how these transactions fitinto an overall financial and asset management strategy and the opportunity tolearn from those with first-hand knowledge of the process."

About Paul Capital Healthcare and Paul Capital Partners

Through its funds, Paul Capital Healthcare is one of the largest dedicatedhealthcare investors globally, with more than $1.4 billion in equity capitalcommitments and debt facilities under management. Combined, the Paul CapitalHealthcare funds have invested more than $940 million in the pharmaceutical,biotechnology, and medical device sectors. These investments are focused oncommercial stage companies and products, and consist of investments in theform of royalties, revenue interests, debt and equity. Additional informationon Paul Capital Healthcare can be found at www.paulcapitalhealthcare.com.Paul Capital Partners manages nearly $5 billion in equity capital commitmentsfor its three investment platforms, which include Paul Capital Healthcare,Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has officesin New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.Contact Information: Paul Capital Healthcare Tel: +44 (0) 20 7514 0754 Ken Macleod, Partner Lazar Partners Tel: +1-646-871-8487 Stephanie Seiler Tel: +1-206-713-0124 Email: [email protected]

SOURCE Paul Capital Healthcare
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close